Avidity Biosciences, Inc.: share-based compensation expense
Share-based compensation expense for Avidity Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Avidity Biosciences, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 97,838,000 | USD | 2026-02-23 | 10-K · 0001599901-26-000031 |
| 2024-01-01 | 2024-12-31 | 51,363,000 | USD | 2026-02-23 | 10-K · 0001599901-26-000031 |
| 2023-01-01 | 2023-12-31 | 38,222,000 | USD | 2026-02-23 | 10-K · 0001599901-26-000031 |
| 2022-01-01 | 2022-12-31 | 27,139,000 | USD | 2025-02-27 | 10-K · 0001599901-25-000059 |
| 2021-01-01 | 2021-12-31 | 17,056,000 | USD | 2024-02-28 | 10-K · 0001599901-24-000025 |
| 2020-01-01 | 2020-12-31 | 4,310,000 | USD | 2023-02-28 | 10-K · 0001599901-23-000009 |
| 2019-01-01 | 2019-12-31 | 406,000 | USD | 2022-03-01 | 10-K · 0001564590-22-008049 |
| 2018-01-01 | 2018-12-31 | 60,000 | USD | 2021-03-15 | 10-K · 0001564590-21-013157 |
Related financial histories
- Avidity Biosciences, Inc.: total assets
- Avidity Biosciences, Inc.: total liabilities
- Avidity Biosciences, Inc.: stockholders equity
- Avidity Biosciences, Inc.: cash and cash equivalents
- Avidity Biosciences, Inc.: net income or loss
- Avidity Biosciences, Inc.: operating cash flow
- Avidity Biosciences, Inc.: capital expenditure payments
- Avidity Biosciences, Inc.: contract revenue excluding tax
- Avidity Biosciences, Inc.: financing cash flow
- Avidity Biosciences, Inc.: investing cash flow
- Avidity Biosciences, Inc.: retained earnings or deficit
- Avidity Biosciences, Inc.: basic weighted-average shares
- Avidity Biosciences, Inc.: diluted weighted-average shares
- Avidity Biosciences, Inc.: basic earnings per share
- Avidity Biosciences, Inc.: diluted earnings per share
- Avidity Biosciences, Inc.: net property, plant and equipment
- Avidity Biosciences, Inc.: operating income or loss
- Avidity Biosciences, Inc.: current assets
- Avidity Biosciences, Inc.: interest expense
- Avidity Biosciences, Inc.: current liabilities
- Avidity Biosciences, Inc.: current accounts payable
- Avidity Biosciences, Inc.: net current accounts receivable
- Avidity Biosciences, Inc.: operating expenses
- Avidity Biosciences, Inc.: research and development expense
Inspect the source
- Entity
- Avidity Biosciences, Inc. / CIK 0001599901
- Captured
- 2026-09-21T17:20:20.082Z
- SEC response SHA-256
a2115d7e8f570058dad08e35568dcb84ba59f6e7e1538c5e66b8f7f7e6ea4685
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001599901.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))